I’m debuting something new: A semi-regular column focused on the ups and downs of small-cap biotech stocks. “Small cap” is defined as a market value of $500 million or less, with some wiggle room, as I see fit. In each column, I’ll choose two or three biotechs to focus on. The facts and the data will be my guide, bulls–t will be called out. I’m taking requests for companies to cover, so reach out to me on Twitter (DMs are open), email, or in the comment section of the column.

In today’s debut small-cap biotech column: Rexahn Pharmaceuticals (REXN) (RNN), Omeros (OMER), and Cel-Sci (CVM).

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy